News
SPRB
1.700
-2.30%
-0.040
Turning Point, Amylyx top healthcare gainers; Novavax, Rallybio lead losers' pack
Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Biosciences (SPRB)...
Seekingalpha · 06/03 14:00
Spruce Biosciences to Participate in June Investor Conferences
SAN FRANCISCO, June 01, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that c...
Business Wire · 06/01 20:01
Spruce Biosciences Announces Abstract For Presentation At ENDO 2022 Annual Conference Jun. 11
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced
Benzinga · 05/31 12:12
Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
SAN FRANCISCO, May 31, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a ...
Business Wire · 05/31 12:00
Top Premarket Decliners
MT Newswires · 05/13 08:18
Spruce Biosciences GAAP EPS of -$0.50 misses by $0.06
Spruce Biosciences press release (NASDAQ:SPRB): Q1 GAAP EPS of -$0.50 misses by $0.06. Cash, cash equivalents and investments as of March 31, 2022, were $108.9 million.
Seekingalpha · 05/11 20:39
BRIEF-Spruce Biosciences Reports First Quarter 2022 Results
reuters.com · 05/11 20:02
Spruce Biosciences to Participate in May Investor Conferences
SAN FRANCISCO, May 03, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that co...
Business Wire · 05/03 20:05
BRIEF-Spruce Biosciences Appoints Libbie Mansell As Chief Regulatory And Quality Officer
reuters.com · 04/11 14:41
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer
SAN FRANCISCO, April 11, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that ...
Business Wire · 04/11 12:00
SPRB, RVMD and LYEL among after hour movers
Gainers: Spruce Biosciences (SPRB) +7%. ThredUp  (TDUP) +7%. Cellectis  (CLLS) +6%. Revolution Medicines (RVMD) +5%. Ocular Therapeutix (OCUL) +5%. Losers: Trean Insurance Group (TIG) -7%. Lyell Immunopharma (LYEL) -6%. Vivid Seats  (SEAT) -6%.
Seekingalpha · 04/08 22:02
Where Spruce Biosciences Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Spruce Biosciences (NASDAQ:SPRB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade...
Benzinga · 03/16 13:14
SVB Leerink Adjusts Spruce Biosciences' Price Target to $3 from $5, Keeps Market Perform Rating
MT Newswires · 03/16 09:11
RBC Cuts Price Target on Spruce Biosciences to $9 From $13, Maintains Outperform Rating, Speculative Risk Qualifier
MT Newswires · 03/15 08:27
Spruce Biosciences GAAP EPS of -$1.81
Spruce Biosciences press release (NASDAQ:SPRB): FY GAAP EPS of -$1.81. FY net loss $42.3M
Seekingalpha · 03/14 21:52
BRIEF-Spruce Biosciences Reports Fourth Quarter And Full Year 2021 Financial Results
reuters.com · 03/14 20:14
Spruce Biosciences hires new Chief Medical Officer
Spruce Biosciences (NASDAQ:SPRB) has appointed Will Charlton, a board-certified pediatric endocrinologist with over 15 years of clinical research experience, as its new Chief Medical Officer. Dr. Charlton will succeed Rosh
Seekingalpha · 03/14 20:11
Spruce Biosciences Names New Chief Medical Officer
MT Newswires · 03/14 16:14
Ladenburg Thalmann Starts Spruce Biosciences at Buy With $6 Price Target
MT Newswires · 03/08 09:05
Spruce Biosciences to Participate in March Investor Conferences
SAN FRANCISCO, March 01, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that ...
Business Wire · 03/01 21:05
More
Webull provides a variety of real-time SPRB stock news. You can receive the latest news about Spruce Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). The Company is also developing Tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. The Company has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with poor disease control and anticipate topline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH with good disease control focused on glucocorticoid reduction and anticipate topline.